Compare Jones Lang LaSalle Inc (JLL) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Novavax Inc — how do they compare? Jones Lang LaSalle Inc trades at $360.7 (market cap $16.72B), while Novavax Inc trades at $7.88 (market cap $1.31B). The key difference: Jones Lang LaSalle Inc is far larger — about 12.8× Novavax Inc's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| JLL | NVAX | |
|---|---|---|
Market Cap | $16.72B | $1.31B |
Sector | Real Estate | Health |
52-Week High | $373.24 | $11.19 |
52-Week Low | $280.16 | $6.22 |
Enterprise Value | $19.48B | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $363.49, up 1.72% today, near its 52-week high. The stock exhibits bullish technical signals with a golden cross and strong momentum, supported by consistent earnings beats in recent quarters. Revenue grew to $26.12B in 2025, with net income margin improving to 3.64%. Analyst consensus is bullish with a $391.50 price target, and institutional holdings show confidence from firms like Bank of America.
Outlook remains positive driven by earnings growth and operational strength, but risks include economic sensitivity and competitive pressures. The stock offers upside to consensus targets, though valuation metrics like P/E of 17.43 require monitoring for sustainability amid market volatility.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
